Organization | Henogen

Henogen Report issue

For profit Phase 2 Phase 3

Founded: Charleroi Belgium (1999)

Status: Acquired by Novasep (2009)

Organization Overview

First Clinical Trial

2006

NCT00291941

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (5)

fendrix (1 trial)

fendrix vaccine (1 trial)

hb-as02v (2 trials)

henogen hb vaccine (1 trial)

hepatitis b vaccine (recombinant) (recombivax) (4 trials)

Drugs in Phase 2 Trials (3)

anti-cd3 conjugated to recombinant ricin a chain (1 trial)

anti-cd7 conjugated to recombinant ricin a chain (1 trial)

ebv vaccine (268664) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Graft vs Host Disease (Phase 2)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial APIs: 8